Watson Loxitane mechanism of action
Executive Summary
Watson should cease using ads for antipsychotic loxapine that "imply mechanism of action by emphasizing affinity for particular receptors," July 22 letter from FDA directs. "The mechanism of action of Loxitane has not been established," FDA said. The agency specifically cited "the presentation 'pinpointing the Loxitane difference,' with the pushpin penetrating flags that represent the D4 dopamine receptor and the 5-HT2 serotonin receptor" as false or misleading